Here's Why VKTX Stock Plummeted 18% on Wednesday

Published on 19 Dec 2024 on Zacks · via Yahoo Finance

CT-388, a dual GLP-1/GIP receptor agonist, is being evaluated for the treatment of obesity in patients with and without type 2 diabetes, injected...

Read the rest of the article

Start tracking your investments with Statfolio

CT-388, a dual GLP-1/GIP receptor agonist, is being evaluated for the treatment of obesity in pat...

Zacks · via Yahoo Finance 19 Dec 2024

On Wednesday, Merck & Co Inc (NYSE:MRK) and Hansoh Pharma, a Chinese biopharmaceutical company,...

Benzinga · via Yahoo Finance 19 Dec 2024

Nvidia, Jabil Surge Among Market Cap Stock Movers on Wednesday

Investing.com 19 Dec 2024

We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In...

Insider Monkey · via Yahoo Finance 17 Dec 2024

The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $47.03, denoting a -1.7...

Zacks · via Yahoo Finance 14 Dec 2024

The Biden-Harris Administration has proposed expanding Medicare and Medicaid coverage for anti-ob...

Benzinga 26 Nov 2024

It has been about a month since the last earnings report for Viking Therapeutics, Inc. (VKTX)....

Zacks · via Yahoo Finance 23 Nov 2024

In a decision made public this week, Chief Administrative Law Judge Clark Cheney found that Vikin...

Law.com 22 Nov 2024

We recently compiled a list of the 11 Reddit Stocks with Biggest Upside Potential. In this articl...

Insider Monkey · via Yahoo Finance 22 Nov 2024

On Tuesday, Viking Therapeutics, Inc. (NASDAQ:VKTX) highlighted the final results from its VOYAGE...

Benzinga · via Yahoo Finance 20 Nov 2024